

Psoriatic arthritis - Pipeline Insight, 2021

<https://marketpublishers.com/r/P93E8AE72D7EN.html>

Date: May 2021

Pages: 80

Price: US\$ 2,000.00 (Single User License)

ID: P93E8AE72D7EN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Psoriatic arthritis - Pipeline Insight, 2021," report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Psoriatic arthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Psoriatic arthritis Understanding

Psoriatic arthritis: Overview

Psoriatic Arthritis is a chronic inflammatory disease of the joints that can be associated with the psoriasis. It can affect both peripheral joints and axial skeleton causing pain, stiffness, swelling and joint destruction. This joint pathology develops gradually and cause more nuisance than disabling. Psoriatic arthritis is considered as seronegative spondyloarthropathies. The fact that it is Seronegative is that the blood tests negative for some factors that is present in rheumatoid arthritis. Spondyloarthropathy describes a group of conditions that all share common characteristics. First, there is a presence of arthritis that affects the spine. Second, inflammation occurs in ligaments, tendons and sometimes in other organs such as the eye.

'Psoriatic arthritis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Psoriatic arthritis pipeline landscape is provided which includes the disease overview and Psoriatic arthritis treatment guidelines. The assessment part of the report embraces, in depth Psoriatic arthritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Psoriatic arthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Psoriatic arthritis R&D. The therapies under development are focused on novel approaches to treat/improve Psoriatic arthritis.

Psoriatic arthritis Emerging Drugs Chapters

This segment of the Psoriatic arthritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Psoriatic arthritis Emerging Drugs

Tildrakizumab: Sun Pharma Global

Tildrakizumab is a humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of the interleukin-23 (IL-23) cytokine and inhibits its interaction with the IL-23 receptor. IL-23 plays a critical role in modulating inflammatory and immune responses. It is currently in preregistration stage for the treatment of psoriatic arthritis.

BMS-986165: Bristol-Myers Squibb

BMS-986165 (Deucravacitinib) is the first and only novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor in clinical studies across multiple immune-mediated diseases. BMS-986165 selectivity is driven by a unique mechanism of action that is distinct from other kinase inhibitors. TYK2 is an intracellular signaling kinase that mediates signaling of IL-23, IL-12 and Type I IFN, which are naturally occurring cytokines involved in inflammatory and immune responses. It is currently in phase 2 of development stage for the treatment of psoriatic arthritis.

AbGn-168H: AbGenomics

AbGn-168H is a humanized therapeutic antibody with a unique mechanism of action, which preferentially induces apoptosis of late-stage activated T cells. This novel activated-T cell apoptosis-inducing antibody effectively eliminates chronic pathogenic T cells while fully maintaining host defense. It is currently in phase 2 of development stage for the treatment of psoriatic arthritis.

Apremilast: 3SBio

Apremilast is being developed by 3SBio for the treatment of psoriatic arthritis and is currently in Phase I of clinical trial study. Apremilast acts as Interleukin 23 inhibitors, tumour necrosis factor alpha inhibitors and type 4 cyclic nucleotide phosphodiesterase inhibitors.

Further product details are provided in the report

Psoriatic arthritis: Therapeutic Assessment

This segment of the report provides insights about the different Psoriatic arthritis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Psoriatic arthritis

There are approx. 35+ key companies which are developing the therapies for Psoriatic arthritis. The companies which have their Psoriatic arthritis drug candidates in the most advanced stage, i.e. preregistration include, Sun Pharma Global.

Phases

DelveInsight's report covers around 35+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Psoriatic arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravitreal

Subretinal

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Psoriatic arthritis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Psoriatic arthritis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Psoriatic arthritis drugs.

Psoriatic arthritis Report Insights

Psoriatic arthritis Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Psoriatic arthritis Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Psoriatic arthritis drugs?

How many Psoriatic arthritis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Psoriatic arthritis?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Psoriatic arthritis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Psoriatic arthritis and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Sun Pharma Global

UCB Biopharma

Pfizer

Bristol-Myers Squibb

AbGenomics

Boehringer Ingelheim

Affibody

AltruBio

Synact Pharma

NeuClone

3SBio

Qyuns Therapeutics

Kangpu Biopharmaceuticals

Alpine Immune Sciences

Avotres

Xbrane Biopharma

XBiotech

Evelo

Luye Pharma Group

Levolta Pharmaceuticals

DNX Biopharmaceuticals

Mycenax Biotech

Key Products

Tildrakizumab

Bimekizumab

PF-06700841

BMS-986165

AbGn-168H

BI 730357

Izokibep

Neihulizumab

AP1189

NeuLara

Apremilast

QX 002N

KPG-612

ALPN 101

AVT001

Xcimzane

RHE 70202

EDP1815

DNX 514

DNX 114

Contents

Introduction

Executive Summary

Psoriatic arthritis: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Psoriatic arthritis – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Psoriatic arthritis companies' collaborations, Licensing, Acquisition -Deal Value

Trends

Psoriatic arthritis Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Preregistration)

Comparative Analysis

Tildrakizumab: Sun Pharma Global

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

BMS-986165: Bristol-Myers Squibb

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....
Early Stage Products (Phase I)
 Comparative Analysis
Apremilast: 3SBio
 Product Description
 Research and Development
 Product Development Activities
Drug profiles in the detailed report.....
Preclinical and Discovery stage Products
 Comparative Analysis
ALPN 101: Alpine Immune Sciences
 Product Description
 Research and Development
 Product Development Activities
Drug profiles in the detailed report.....
Inactive Products
 Comparative Analysis
Psoriatic arthritis Key Companies
Psoriatic arthritis Key Products
Psoriatic arthritis- Unmet Needs
Psoriatic arthritis- Market Drivers and Barriers
Psoriatic arthritis- Future Perspectives and Conclusion
Psoriatic arthritis Analyst Views
Psoriatic arthritis Key Companies
Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Psoriatic arthritis
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Psoriatic arthritis
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Psoriatic arthritis - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/P93E8AE72D7EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P93E8AE72D7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970